Panacea Biotec's Q4 FY 2025-26 Quarterly Results

Result Summary

• Panacea Biotec Ltd reported a 1.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 20.0%.
• Its expenses for the quarter were up by 5.8% QoQ and 2.6% YoY.
• The net profit decreased 125.7% QoQ and decreased 49.7% YoY.
• The earnings per share (EPS) of Panacea Biotec Ltd declined at 0.08 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Panacea Biotec Ltd is a well-established entity in the pharmaceutical industry. It primarily focuses on the development, manufacturing, and marketing of vaccines and pharmaceutical formulations. The company has been a key player in the vaccines segment, contributing significantly to public health through its range of products. Panacea Biotec's operations are structured to cater to both domestic and international markets, with a portfolio that encompasses a variety of therapeutic areas. As of the latest updates available up to October 2023, no specific recent major developments are noted; hence, any new strategic moves or product launches by the company remain unspecified in the current context.

Revenue

In Q4FY26, Panacea Biotec Ltd reported a total income of ₹169.30 crores, marking a 1.1% increase from the previous quarter, Q3FY26, where the income was ₹167.47 crores. Compared to Q4FY25, which recorded a total income of ₹141.12 crores, there is a notable year-over-year (YoY) increase of 20.0%. This upward trend in revenue reflects the company's capacity to sustain its income growth over both the quarterly and annual periods. The company's revenue performance over these periods suggests a positive momentum in its financial operations.

Profitability

The profitability metrics for Panacea Biotec Ltd indicate a challenging quarter in Q4FY26. The company recorded a loss before tax of ₹1.25 crores, which contrasts sharply with the profit before tax of ₹6.49 crores in Q3FY26. This represents a quarter-over-quarter (QoQ) decline of 119.3%. On a year-over-year basis, the loss before tax increased significantly from a marginal loss of ₹0.04 crores in Q4FY25. The tax expense in Q4FY26 was negative at ₹0.25 crores, compared to a tax expense of ₹2.60 crores in Q3FY26 and ₹1.95 crores in Q4FY25, showing a substantial change in tax obligations. Consequently, the profit after tax in Q4FY26 was a loss of ₹1.00 crore, a significant decrease from a profit of ₹3.89 crores in Q3FY26, and a reduction from the loss of ₹1.99 crores in Q4FY25. Earnings per share also reflected this trend, with a negative EPS of ₹0.08 in Q4FY26 compared to ₹0.65 in Q3FY26 and a negative ₹0.31 in Q4FY25.

Operating Metrics

The operating expenses for Q4FY26 amounted to ₹173.26 crores, which is a 5.8% increase from the ₹163.75 crores reported in Q3FY26. When compared to Q4FY25, where total expenses were ₹168.87 crores, there is a year-over-year increase of 2.6%. This indicates a rise in the company’s operating costs over both the quarterly and annual periods. The increase in expenses has played a significant role in the company’s profitability metrics for the quarter. The analysis of operating metrics highlights the importance of managing costs in relation to income generation, as seen in the financial data provided for the current and comparable periods.